newsfilter
← Latest News
Business Wire·

Appili Therapeutics Announces Last Patient Enrolled in Phase 3 Trial of Oral Avigan®/Reeqonus™ for the Treatment of Mild-to-Moderate COVID-19

More than 1,200 patients enrolled in the United States, Mexico, and Brazil Study expected to include patients with top priority COVID-19 variants, including Delta Appili Therapeutics Inc. (TSX:APLI, OTCQX:APLIF) (the "Company" or "Appili"), a biop